Clinical Trial Update: Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study to determine the optimal biologic dose of CC-401 in high-risk myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CC-401

Snippet

Sponsor: Celgene Corporation | Conditions: Myeloid Leukemia | Phase 1 | Status: TERMINATED